Research programme: insulin lispro biosimilar - Wockhardt

Drug Profile

Research programme: insulin lispro biosimilar - Wockhardt

Latest Information Update: 27 Aug 2013

Price : $50

At a glance

  • Originator Wockhardt
  • Class Antihyperglycaemics; Insulins; Pancreatic hormones
  • Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Type 1 diabetes mellitus

Most Recent Events

  • 27 Aug 2013 No development reported for Type-1 diabetes mellitus in India (SC)
  • 24 Jan 2013 Wockhardt withdraws its plans for a phase III trial in Type 1 diabetes mellitus in USA (NCT01398670)
  • 24 Jan 2013 Wockhardt withdraws its plans for three phase I trials in Volunteers in USA (NCT01400802, NCT01399255, NCT01400789)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top